
NYSEHealthcareMedical - Instruments & Supplies
أحدث البيانات المتاحة
17.205 US$
−0.135 US$ · -0.78%
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
جلسة التداول العادية
17.205 US$
−0.135 US$ · -0.78%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
نطاق اليوم
السعر الحالي 17.205 US$
نطاق 52 أسبوعًا
السعر الحالي 17.205 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
52
قيمة عادلة
المشاعر
57
مختلط
المخاطر
31
مخاطر متوسطة
الزخم
41
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
نطاق اليوم
السعر الحالي 17.205 US$
نطاق 52 أسبوعًا
السعر الحالي 17.205 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 5.1 مليار USD | 4.79 مليار USD | 4.15 مليار USD | 3.77 مليار USD | 3.77 مليار USD |
| تكلفة البضاعة المباعة | 2.31 مليار USD | 1.87 مليار USD | 1.64 مليار USD | 1.52 مليار USD | 1.47 مليار USD |
| الربح الإجمالي | 2.79 مليار USD | 2.92 مليار USD | 2.5 مليار USD | 2.25 مليار USD | 2.3 مليار USD |
| البحث والتطوير | 371 مليون USD | 343 مليون USD | 324 مليون USD | 307 مليون USD | 271 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 2.23 مليار USD | 2.08 مليار USD | 1.74 مليار USD | 1.48 مليار USD | 1.39 مليار USD |
| نفقات التشغيل | 2.61 مليار USD | 2.76 مليار USD | 2.37 مليار USD | 2.04 مليار USD | 1.97 مليار USD |
| دخل الفوائد | 12 مليون USD | 15 مليون USD | 15 مليون USD | 6 مليون USD | — |
| مصاريف الفوائد | 431 مليون USD | 399 مليون USD | 283 مليون USD | 146 مليون USD | — |
| الاستهلاك والإطفاء | 421 مليون USD | 436 مليون USD | 382 مليون USD | 379 مليون USD | 415 مليون USD |
| الدخل التشغيلي | 188 مليون USD | 162 مليون USD | 130 مليون USD | 207 مليون USD | 329 مليون USD |
| صافي الدخل | −360 مليون USD | −317 مليون USD | −260 مليون USD | 6 مليون USD | 182 مليون USD |
تم تحديث حقائق الشركة 8 أكتوبر 2026.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Ballast Small/Mid Cap ETFMGMT2.44 مليون1.48%164.57 مليون USD1.17%49.125 US$-0.02%
Dimensional World ex U.S. Core Equity 2 ETFDFAX263.26 ألف0.00%12.37 مليار USD0.28%36.765 US$-0.85%
Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDN160.04 ألف0.05%350.91 مليون USD0.47%45.328 US$-0.84%
Gotham 1000 Value ETFGVLU104.95 ألف0.04%242.77 مليون USD0.65%27.475 US$+1.09%
Dimensional - International Core Equity 2 ETFDFIC44.36 ألف0.00%15.01 مليار USD0.22%37.255 US$-0.23%
BNY Mellon US Small Cap Core Equity ETFBKSE28.89 ألف0.03%83.56 مليون USD0.04%41.595 US$-0.06%
Ballast Small/Mid Cap ETFMGMT
Dimensional World ex U.S. Core Equity 2 ETFDFAX
Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDN
Gotham 1000 Value ETFGVLU
Dimensional - International Core Equity 2 ETFDFIC
BNY Mellon US Small Cap Core Equity ETFBKSEالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.